Teva Pharma strong sales growth helped by acquisitions
Israel-headquartered Teva Pharmaceutical Industries (Nasdaq: TEVA) reported fourth-quarter 2011 results with 28% growth in net revenues to $5.7 billion, driven by generic products revenues of $3.0 billion (+12%), branded products sales of $2.3 billion (+68%), and over-the-counter (OTC) net revenues of $215 million.
Non-GAAP net income for the quarter was $1.4 billion and $1.59 a share, in line with consensus expectations. Cash flow from operations was $1.4 billion, and free cash flow was $958 million. Full-year 2011 net revenues totaled $18.3 billion, up 14%, with Non-GAAP earnings per share of $4.97, a rise of 9%
4th-qtr revenues by geographies
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze